GBA1 and Parkinson disease: This was observed in recent data published by Prevail Therapeutics, which demonstrated significantly increased GCase activity in the CSF in a patient following treatment with PR001,35 although the patient in this report was homozygous for GBA1 mutations, which does not reflect most patients with PD and GBA1.